Company intelligence / Profile preview

Amicus Therapeutics

Princeton, New Jersey, United Statesamicusrx.com ↗

Ownership: Public · FOLD
Employees: ~500
Development stage: Commercial

Overview

Amicus has FDA-approved products including Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for late-onset Pompe disease in adults. The company received FDA approval for Pombiliti + Opfolda in September 2023.

Therapeutic areas: Rare DiseasesDermatology
Modalities: Small molecules (pharmacological chaperones)enzyme replacement therapy
Industry: Biotech

Drug pipeline

15 assets

cipaglucosidase alfa

Approved

14 more assets in the full pipeline.

Request access →

Partnerships

Previously had partnerships with Shire (terminated 2009)GlaxoSmithKline (terminated 2013)financing collaboration with Blackstone (2023)

Financials

Market cap: $4.5B
Total revenue: $185.2M
Enterprise value: $4.7B

Beyond the preview

Go deeper on Amicus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amicus Therapeutics.

Explore the full profile